Nanologica Carries out a Directed Share Issue to Guarantors in Connection with the Completed Rights Issue

The Board of Directors of Nanologica AB (publ) (“Nanologica” or the “Company”) has today, pursuant to the authorisation granted by the Annual General Meeting on 21 May 2026, resolved on a directed issue of 1,590,747 units, corresponding to 15,907,470 shares, to certain guarantors in the Company’s recently completed rights issue (the “Rights Issue”), in accordance with the previously announced guarantee agreements (the “Compensation Issue”). The subscription price in the Compensation Issue is SEK 1.68 per unit, corresponding to SEK 0.168 per share. Payment will be made by setting off the guarantors’ claims for guarantee compensation against the subscription amount.

Background

On 19 November 2026, Nanologica announced the outcome of the Rights Issue, for which the subscription period ended on 17 November 2026. Following the utilisation of guarantee commitments, the Rights Issue was subscribed to approximately 77.55 percent and will provide the Company with approximately SEK 85.7 million before deduction of issue costs and set-off of claims.

Guarantee compensation and the Compensation Issue

As previously announced, Ardena is entitled to guarantee compensation of 14 percent of the guaranteed amount in the form of newly issued units. For Bergs Securities AB’s bottom guarantee commitment, compensation is payable in cash at 10 percent of the guaranteed amount or, at Bergs Securities AB’s option, in the form of newly issued units at 14 percent of the guaranteed amount. Bergs Securities AB has elected to receive all of its guarantee compensation in the form of newly issued units.

The Compensation Issue comprises a total of 1,590,747 units, corresponding to 15,907,470 shares. The subscription price is SEK 1.68 per unit, corresponding to SEK 0.168 per share, which is the same as the subscription price in the Rights Issue. Payment will be made in full by setting off the guarantors’ claims for guarantee compensation against the subscription amount. Accordingly, the Company will receive no cash proceeds from the Compensation Issue.

The Compensation Issue does not include the guarantee compensation payable to T&M Participation AB, through which the Chairman of the Board, Thomas Eldered, provided a top guarantee commitment. A proposal concerning the guarantee compensation payable to T&M Participation AB has been submitted for approval at the Extraordinary General Meeting on 30 November 2026. No compensation is payable for Sterling Pharma Solutions’ top guarantee commitment

Reasons for deviating from shareholders’ preferential rights

The reason for deviating from shareholders’ preferential rights is to fulfil the Company’s obligations to Bergs Securities AB and Ardena Gent NV under the previously announced guarantee agreements. The Compensation Issue enables the guarantors to set off their claims for guarantee compensation against the subscription amount for the newly issued units. The Board of Directors considers that settling the guarantee compensation in units rather than cash benefits the Company’s financial position and is in the interests of its shareholders, as it preserves the Company’s cash resources.

Number of shares, share capital and dilution

The Compensation Issue will increase the number of shares in Nanologica by 15,907,470 and the share capital by SEK 318,149.40. Following the Rights Issue and the Compensation Issue, the Company will have 854,571,322 shares and a share capital of SEK 17,091,426.44. The Compensation Issue will result in dilution of approximately 1.86 percent of the shares and votes in the Company, calculated by dividing the number of new shares issued in the Compensation Issue by the total number of shares outstanding following the Rights Issue and the Compensation Issue.

Advisers

Nanologica has engaged Redeye AB, Bergs Securities AB and Navia Corporate Finance AB as Joint Bookrunners, and Advokatfirman Lindahl KB as legal adviser in connection with the Rights Issue. Bergs Securities AB is also acting as issuing agent in connection with the Rights Issue.

 

2026-11-21 Nanologica Carries Out a Directed Share Issue to Guarantors in Connection with the Completed Rights Issue

Share this: